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reintroduced at the end of 1995 after a redesign of the
attachment system and the hook configuration made the
hooks 280 times stronger during fatigue bench testing.
No new fractures have been noted with the new design in
nearly 3000 implants since that time. The new graft has
not been modified, although the deployment system and
handle underwent a significant overhaul before phase III
started in 1998. The new deployment catheter, the
Ancure (Guidant Cardiac and Vascular Division, Menlo
Park, Calif) endograft system, has serial interlocks to guide
a simplified deployment process. This system was used
during the phase III trials. The results of patients enrolled
in phase II and the first 89 patients enrolled in phase III
that were presented to a Food and Drug Administration
(FDA) panel in June 1999 resulted in approval for distri-
bution in September 1999.
DESCRIPTION OF THE DEVICE
The implanted endografts deployment during phase II
that used the old deployment system and during phase III
that used the Ancure system are identical. The fabric is a
woven polyester material that is similar to the standard
surgical grafts. The attachment systems are manufactured
from elgiloy and are hand sutured to the graft. The prox-
imal attachment system consists of a Z frame and four V-
shaped double hooks (Fig 2). The hooks are intended to
penetrate the arterial wall with the assistance of a balloon
inflated to 2 atm. A variation of this system is present on
the distal end of all configurations. The bifurcated implant
is a unibody single-piece construction similar to surgically
implanted bifurcated grafts. The lateral edges of the
Endovascular Technologies (EVT) was founded in
1989 to develop an endovascular graft to treat abdominal
aortic aneurysms (AAAs). The concept was based on the
work of Harrison Lazarus, MD, from the early 1980s
when he successfully implanted a polyester tube graft with
attached staples into a sheep aorta using a modified endo-
tracheal tube and followed some of the implants for 6
months. Wesley Moore, MD, performed the first human
implantation of an EVT tube graft at the University of
California, Los Angeles, Medical Center in February
1993. It was the first industry-manufactured device to
enter clinical trials in the United States. A bifurcated
design was introduced in late 1994, and later an aorto-
monoiliac configuration was added (Fig 1). Guidant
Corporation acquired EVT in 1997 and continued the
development of the system.
Trial enrollment was halted in early 1995 after hook
breaks were discovered on an explanted graft during a late
open surgical conversion for a persistent endoleak. Many
additional patients were subsequently discovered to have
hook and frame breaks in the attachment systems during
routine radiography. The second generation of grafts was
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The Ancure endografting system: An update
Michel S. Makaroun, MD, Pittsburgh, Pa
The Ancure endografting system (Guidant Cardiac and Vascular Division, Menlo Park, Calif) features a unibody, non-
supported woven polyester graft designed to treat abdominal aortic aneurysms. It is constructed in tube, bifurcated, and
aortoiliac configurations. The attachment system consists of a frame with four independent V-shaped double hooks that
penetrate the arterial wall for fixation. There are separate attachment systems at the proximal and distal ends of the endo-
prosthesis. In September 1999, the Food and Drug Administration (FDA) approved the tube and bifurcated devices for
general use. The aortoiliac device is under present consideration of the FDA. Phase II and III clinical trials of the sys-
tem enrolled over 870 patients from the end of 1995 to the summer of 1999. The device was deployed successfully in
90% to 96% of cases, depending on the configuration and the phase of the trial. Mortality rates were similar to those of
concurrent open surgical control rates, but serious morbidity was reduced. Long-term follow-up of the bifurcated group
from phase II showed only one migration and no ruptures. Aneurysm size reduction in this group was noted in 51.3%
of patients at 1 year and 68.5% at 2 years. In the same subset, type I endoleaks were noted in 2.7% at 1 year and 1.3%
at 2 years. All postoperative imaging studies were reviewed by a core laboratory facility. The advantages of the Ancure
system include solid fixation, flexibility in accommodating morphologic changes, and excellent long-term clinical per-
formance. The disadvantages include a large introducer system and the potential for limb obstruction by compression or
angulation. However, limb compromise responds well to intraluminal stenting. The expected FDA approval of the aor-
toiliac device and a larger variety of graft sizes should expand the number of patients who can be treated with this sys-
tem. (J Vasc Surg 2001;33:S129-34.)
implant contain radiopaque markers to facilitate visualiza-
tion of the endograft during deployment and follow-up.
The Ancure catheter is typically advanced through a
sheath with dual valves to reduce blood loss. The deploy-
ment of the graft with the Ancure system is achieved from
a single handle with multiple controls for the independent
release of the proximal and ipsilateral distal attachment
systems and the manipulation of the included aortic bal-
loon. The contralateral attachment system deployment in
bifurcated grafts is achieved through a special proprietary
torque catheter that is introduced from the contralateral
femoral artery.
CLINICAL TRIALS
An exhaustive description of all the clinical trials and
their results is beyond the scope of this update. Because
the bifurcated devices presently account for more than
90% of the grafts used, their results will be highlighted.
Two-year data on a large number of patients have now
been collected and analyzed for the bifurcated graft; the
salient features will be outlined. Two-year outcome analy-
sis for patients with the tube and aortoiliac grafts has not
been completed yet, but the results at 12 months are
included.
All imaging-based data reflect the interpretation of
independent observers at a core laboratory facility that was
established at the Cleveland Clinic, unless otherwise
noted. Clinical data was collected at the investigation sites
and duly monitored. Our group at the University of
Pittsburgh Medical Center participated actively in both
phase II and III trials.1-5
Phase I clinical trial
The devices implanted during this phase coincided
mostly with the use of the first generation attachment sys-
tem that developed hook and frame fractures. Patients who
were treated during this phase from 1993 to early 1995
received 102 tubes and 12 bifurcated grafts. Several patients
experienced problems with migration and endoleaks and
required conversion. Four patients in this group experi-
enced rupture of the AAA during the last 5 years. 
Phase II trials
Separate multicenter phase II trials were conducted
for each configuration. A prospectively enrolled, concur-
rent open surgical group served as a control arm for all
three trials. This cohort was enrolled during the first phase
II trial that evaluated the tube endograft. All patients
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Fig 1. The Ancure endograft is manufactured in three configurations: tube, bifurcated, and aortoiliac.
Fig 2. The proximal attachment system of the Ancure graft.
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enrolled in the trial were acceptable surgical candidates
and well matched, except for anatomic considerations.
Patients with a proximal aortic neck at least 15 mm in
length and a distal neck at least 12 mm in length under-
went implantation with a tube endograft. An aortic neck
size not to exceed 26 mm in diameter and at least one suit-
able iliac artery to introduce the device were also required.
Patients who were anatomically not suited for the tube
endograft were enrolled in the standard surgical arm, if
they fit all other inclusion criteria and signed an informed
consent. Most patients did not qualify for the tube endo-
graft because of the absence of a satisfactory distal neck
length. 
The bifurcated and aortoiliac trials were activated later
than the tube trial. Investigative centers participated in
one, two, or all three trials. Anatomic considerations dic-
tated which endograft configuration to use and in which
phase II trial subsequent patients would be enrolled. A
total of 542 patients were enrolled to receive 153 tubes
and 268 bifurcated and 121 aortoiliac grafts. Standard
open procedures were performed on 111 patients as part
of the control group.
Demographics and risk factors were similar among
groups. A notable exception is that few female patients
qualified for the endovascular treatment arms, mainly
because of small or diseased iliac arteries. The deployment
success rate (defined as successful implantation in the
desired location) exceeded 90% with all endograft config-
urations. Results were based on an intent to treat analysis,
and all patients who were enrolled were included in the
analysis whether or not they received an endograft. Blood
loss, use of the intensive care unit, and hospital length of
Fig 3. Survival by life table analysis of tube (A) and bifurcated (B) configurations in patients (broken line) compared with open surgical
control subjects (solid line).
A
B
stay were reduced in all endograft groups compared with
the control subjects. The reductions were statistically sig-
nificant.
Mortality and morbidity. Perioperative mortality
and selected morbidity parameters are presented in Table I
for the patients who were treated with tube or bifurcated
endografts and control patients. Mortality rates were similar
among groups, with no deaths noted in the tube endograft
group. Blood loss and cardiac and pulmonary morbidity
were significantly reduced in the endograft groups. Graft
thrombosis and renal complications, most of them mild and
temporary, were increased in the bifurcated group.
Aneurysmal sac shrinkage. The salient late results
are detailed in Table II. Reduction in AAA size was
defined as at least a 5-mm reduction in the largest AAA
diameter on computed tomography scan. Of the bifur-
cated grafts, 51.3% grafts were associated with an AAA size
reduction at 1 year and 68.5% at 2 years. AAA shrinkage
occurred less often in patients with endoleaks. A limited
number of patients showed sac expansion that was associ-
ated with an endoleak. One AAA enlarged in the absence
of any demonstrable endoleak.
Endoleaks. Endoleak rates presented in Table II were
tabulated from core laboratory data that were based on
review of contrast computed tomography scans and color
Duplex ultrasound scans. At 12 months endoleaks were
present in 25% of patients who were treated with a tube
graft and 30% of patients who were treated with a bifur-
cated graft. The incidence of type I endoleaks still present
at 1 and 2 years, however, is very small, with a consider-
able number of type II endoleaks. These reported rates
deserve additional discussion. Discrepancies in reported
endoleaks between the core laboratory and investigators
persisted throughout the study. Investigators diagnosed
endoleaks less than one half as often as the core laboratory.
The availability of all computed tomography raw data to
investigators may have allowed a better analysis of ques-
tionable cases. The high rate of shrinkage of the AAA
(30%-40%) in the presence of the endoleaks reported by
the core laboratory seems to support the diagnosis of the
investigators. 
Secondary interventions to correct endoleaks were not
common. Only two late open conversions at 4 months and
7 months were performed for proximal endoleaks with
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Table II. Late results of Ancure grafts in patients enrolled in phase II trials
Tube Bifurcated Aortoiliac
%AAA shrinkage
12 Months 43 (44/103) 51.3 (96/187) 58 (38/65)
24 Months N/A 68.5 (61/89) N/A
%AAA expansion (%)
12 Months 5.8 (6/103) 2.1 (4/187) 4.6 (3/65)
24 Months N/A 1.1 (1/89) N/A
%Endoleaks at 12 months (%)
Type I 3.8 (4/104) 2.7 (5/196) 2.9 (2/69)
Type II 19.2 (20/104) 21.9 (43/196) 21.7 (15/69)
Indeterminate 1.9 (2/104) 5.1 (10/196) 7.2 (5/69)
%Endoleaks at 24 months
Type I N/A 1.1 (1/92) N/A
Type II N/A 19.6 (18/92) N/A
Late surgical conversions* (n) 1 2 1
Ruptures (n) 0 0 0
Attachment system failures (n) 0 0 0
Proximal system migration (n) 0 1 0
N/A, Final analysis not available yet.
*Twelve months for tube and aorto-iliac configurations; 24 months for bifurcated configuration.
Table I. Death and selected morbidity in phase II tube and bifurcated configurations in patients compared with open
surgical control subjects
Tube (n = 153) Bifurcated (n = 268) Control (n = 111) P value
Deaths (%) 0 7 (2.6) 3 (2.7) NS
Respiratory complications (%) 11 (7)* 27 (10)* 25 (22) <.01*
Cardiac complications (%) 16 (11)* 36 (13) 23 (21) <.01*
Bleeding (%) 13 (9)* 42 (16) 44 (40) <.01*
Bowel complications (%) 8 (5) 8 (3) 9 (8) NS
Wound complications (%) 8 (5) 9 (3) 2 (2) NS
Renal insufficiency (%) 5 (3) 22 (8)* 2 (2) .02*
Graft thrombosis (%) 0 7 (3)* 0 <.01*
NS, Not significant.
*Statistical significance is compared with control subjects.
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bifurcated grafts, and only one was performed with a tube
graft. Because the protocols did not dictate or suggest
possible remedies for endoleaks, treatment regimens var-
ied considerably among centers. Watchful follow-up, coil-
ing, limited revisions, or conversions were all used to a
varying degree. The collective experience of all investiga-
tors is not available because interventions were typically
late, with no review of interventions by the core labora-
tory. At the University of Pittsburgh, we performed arte-
riography and coiling of all persistent endoleaks at 6
months (10% of patients with implants), which resulted in
a low incidence of endoleaks at 1 year (3%) and none at 2
years. This treatment modality has been very effective in
our hands.2,3,5
Late results. During the follow-up of all patients who
were enrolled in the trials after 1995, no attachment sys-
tem failures or ruptures have been noted so far. One 10-
mm migration in a bifurcated proximal attachment system
was noted at 1 year. The migration was associated with
neck dilatation (>6 mm). No endoleak or AAA expansion
was noted with this migration. At least one patient who
was treated with a tube endograft had a cephalad migra-
tion of the inferior end of the graft at 2 years. He was suc-
cessfully treated with a second graft that was carried to the
iliac level. This type of migration is due to effacement of
the distal neck that is known to be prone to significant
enlargement over time.6 This complication can easily be
avoided by the use of only tube grafts in patients with a
long distal neck.
Phase III trials
The phase III trials have used the new deployment sys-
tem of the Ancure endograft but the identical implant.
Enrollment started in early 1998 and terminated with the
FDA approval in September 1999. Preoperative parame-
ters were similar to those in the phase II trials. Tube
devices were implanted in 41 patients, and bifurcated
endografts were implanted in 290 of 352 patients who
enrolled in the phase III study. Deployment success was
94%. Operating time was initially higher for the new
Ancure deployment system, presumably because of the
learning curve. Because the deployment technique was
different, there were more reported twists (9%) with the
early Ancure experience. This improved significantly over
time. It is our distinct feeling at the University of
Pittsburgh that a greater accuracy of placement of the
proximal attachment system is achieved with the new
deployment system.
An analysis of the results after 182 patients with the
bifurcated Ancure grafts were enrolled in phase III
showed some significant differences from phase II patients
with bifurcated endografts. The median hospital stay
decreased from 3 to 2 days; cardiac complications
decreased from 13.4% to 5.5%, and pulmonary complica-
tions decreased from 10.1% to 1.1%. Most of the differ-
ences are likely due to better case selection and more
familiarity with the new technology. The incidence of
endoleaks as estimated by the investigators at discharge
among 290 patients (26.6%) was similar to the incidence
during phase II (24.3%). The author, however, noted a
considerable reduction of endoleaks during this phase of
the trials.5
SPECIAL ISSUES
Rupture. Rupture of the AAA after endovascular
treatment has been reported by many authors, including
the recent publication of a significant series after repair
with a commercially available device in the United States.7
No ruptures have yet been encountered in the United
States with the use of the Ancure grafts that were
implanted after the attachment system was revised at the
end of 1995. However, a case of rupture has recently been
encountered in Germany. The patient underwent a tube
endograft implantation in June 1996. Follow-up in
August 1997 showed no abnormalities. The patient
refused further evaluation until he experienced a rupture
in March 2000. The distal attachment had migrated
cephalad because of effacement of the distal neck during a
period of 3 years with no observation. The patient sur-
vived the emergency conversion to open repair. This case
highlights the necessity for lifelong follow-up.
Limb obstruction. The limbs of the Ancure graft are
not supported and are thus prone to the development of
luminal compromise from a variety of sources. Heavy dis-
tal aortic calcifications or proximal iliac stenoses can result
in compression of the lumen. Graft folds that develop
from oversized limbs or angulated and tortuous iliac arter-
ies can also be the cause of obstruction. Patients were eval-
uated early in phase II with limb occlusions before this was
commonly appreciated. Limb occlusions were treated by a
variety of interventional means, such as lytic therapy or
surgical options (eg, femorofemoral bypass grafting).
Increased awareness of the problem prompted routine
careful assessment of limb flow in the operating room
before the termination of the procedure. Intravascular
ultrasound scanning is best suited for this task, but other
methods have been used. When luminal compromise is
noted, kissing balloon dilatation or elgiloy stent placement
(such as WallStent; Boston Scientific, Boston, Mass) in the
lumen usually prevents further problems and has been suc-
cessful in more than 97% of patients. During phase II tri-
als, 38% of patients with bifurcated implants were noted to
have at least some degree of limb abnormalities that were
sufficient to require additional intervention. However,
only 10.3% of patients (one fourth of those affected) man-
ifested problems after operation. In the early part of the
phase III trial, only two of 77 patients (3%) needed treat-
ment for limb abnormalities after operation.
Long-term survival. One of the yardsticks in com-
paring therapies is the effect on long-term survival. So far,
endovascular AAA treatment with the Ancure endograft
has resulted in essentially identical long-term survival
when compared with standard surgical repair. Survival
curves for patients with tube and bifurcated implants that
are compared with control subjects are shown in Fig 3.
TOTAL CLINICAL EXPERIENCE
The Ancure endograft system has been available to
selected centers in Europe and Australia for many years; it
is estimated that more than 500 patients have undergone
implantation procedures outside the United States.
Because of the FDA approval, more than 2000 cases have
been performed in the United States, expanding the total
experience to more than 3000 patients. More than one
half of the total implantations occurred recently. 
Training, as mandated by the FDA, has so far con-
sisted of a 2-day course that includes didactic sessions,
hands on deployment in flow models, and observation of
cases in the operating room. Typically, a two-member
team with satisfactory AAA surgical volume and interven-
tional skills is trained at the same time. From October
through May 1, 2000, Guidant Cardiac and Vascular
Division has trained 828 physicians: 537 surgeons, 229
radiologists, and 60 cardiologists. Clinical experience at all
these new centers is difficult to evaluate. The technical
success rate, however, as reported by clinical monitors is
approximately 95%.
SUMMARY 
The Ancure endograft was the first commercially pro-
duced graft to undergo trials in the United States; FDA
approval was granted in September of 1999. Some
improvements in the attachment and delivery systems
were necessary along the way, which resulted in excellent
long-term results to date. This technology remains fairly
novel, despite giant steps forward during the last decade.
Further improvements and innovations are to be expected,
delivering on the promise to make treatment of AAA a
fairly effective and minimally invasive reality.
I thank Maria Decker, MD, from Guidant Cardiac and
Vascular Division for collecting data and providing the latest
information available for this update.
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